Refractory dermatomyositis and polymyositis in adults: Treatment options

Dermatomyositis and polymyositis are rare autoimmune diseases, classified as inflammatory myopathies, clinically characterized by muscle weakness, frequently accompanied by extramuscular manifestations. Patients usually achieve remission or low levels of disease activity with initial treatment with...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2023
Institución:
Pontificia Universidad Javeriana Cali
Repositorio:
Vitela
Idioma:
spa
OAI Identifier:
oai:vitela.javerianacali.edu.co:11522/524
Acceso en línea:
https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308
https://vitela.javerianacali.edu.co/handle/11522/524
Palabra clave:
Dermatomiositis
Polimiositis
Terapéutica
Acciones farmacológicas
Miositis
Polymyositis
Dermatomyositis
Treatment
Pharmacotherapy
Myositis
Rights
License
Derechos de autor 2023 Salutem Scientia Spiritus
id Vitela2_832eda2679058026029971947774734e
oai_identifier_str oai:vitela.javerianacali.edu.co:11522/524
network_acronym_str Vitela2
network_name_str Vitela
repository_id_str
spelling Guerrero-Oviedo, María CamilaMoreno-Gomez , Freddy2023-03-302023-10-11T04:35:20Z2023-10-11T04:35:20Zhttps://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308https://vitela.javerianacali.edu.co/handle/11522/524Dermatomyositis and polymyositis are rare autoimmune diseases, classified as inflammatory myopathies, clinically characterized by muscle weakness, frequently accompanied by extramuscular manifestations. Patients usually achieve remission or low levels of disease activity with initial treatment with glucocorticoids (may or may not be combined with immunomodulators), when this fails, it is considered refractory dermatomyositis and polymyositis (a new muscle biopsy must first be performed to rule out alternative diagnoses), thus additional treatments will be required for its management. The treatment of refractory dermatomyositis and polymyositis continues to be a challenge due to the lack of scientific evidence to validate the effectiveness of alternative drugs. This review presents some of the therapeutic alternatives. Biological therapies, especially rituximab and abatacept, were found in the literature as promising to reduce morbidity and mortality in both pathologies.La dermatomiositis y polimiositis son enfermedades autoinmunes raras, clasificadas dentro de las miopatías inflamatorias, y caracterizadas clínicamente por debilidad muscular, frecuentemente acompañada de manifestaciones extramusculares. Los pacientes usualmente logran la remisión o niveles bajos de actividad de la enfermedad con el tratamiento inicial con glucocorticoides (pueden o no estar asociados a inmunomoduladores), cuando este falla se considera una dermatomiositis y polimiositis refractarias (antes se debe realizar una nueva biopsia muscular para descartar diagnósticos alternativos) por lo cual se requerirán tratamientos adicionales para su manejo. El tratamiento de la dermatomiositis y polimiositis refractarias continúa siendo un reto debido a la falta de evidencia científica que permita validar la efectividad de fármacos alternativos. Esta revisión presenta algunas de las alternativas terapéuticas. Se encontró en la literatura como prometedoras para disminuir la morbimortalidad en ambas patologías las terapias biológicas, especialmente el rituximab y abatacept.application/pdfspaPontificia Universidad Javeriana Calihttps://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308/1146Derechos de autor 2023 Salutem Scientia Spiritushttps://creativecommons.org/licenses/by-nc-nd/4.0Salutem Scientia Spiritus; Vol. 9 No. 1 (2023): Revista Salutem Scientia Spiritus; 59-65Salutem Scientia Spiritus; Vol. 9 Núm. 1 (2023): Revista Salutem Scientia Spiritus; 59-652463-1426DermatomiositisPolimiositisTerapéuticaAcciones farmacológicasMiositisPolymyositisDermatomyositisTreatmentPharmacotherapyMyositisRefractory dermatomyositis and polymyositis in adults: Treatment optionsPolimiositis y dermatomiositis refractaria en adultos: Opciones terapéuticasinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisión de la literatura11522/524oai:vitela.javerianacali.edu.co:11522/5242024-06-25 05:12:43.579metadata.onlyhttps://vitela.javerianacali.edu.coRepositorio Vitelavitela.mail@javerianacali.edu.co
dc.title.en-US.fl_str_mv Refractory dermatomyositis and polymyositis in adults: Treatment options
dc.title.es-ES.fl_str_mv Polimiositis y dermatomiositis refractaria en adultos: Opciones terapéuticas
title Refractory dermatomyositis and polymyositis in adults: Treatment options
spellingShingle Refractory dermatomyositis and polymyositis in adults: Treatment options
Guerrero-Oviedo, María Camila
Dermatomiositis
Polimiositis
Terapéutica
Acciones farmacológicas
Miositis
Polymyositis
Dermatomyositis
Treatment
Pharmacotherapy
Myositis
title_short Refractory dermatomyositis and polymyositis in adults: Treatment options
title_full Refractory dermatomyositis and polymyositis in adults: Treatment options
title_fullStr Refractory dermatomyositis and polymyositis in adults: Treatment options
title_full_unstemmed Refractory dermatomyositis and polymyositis in adults: Treatment options
title_sort Refractory dermatomyositis and polymyositis in adults: Treatment options
dc.creator.none.fl_str_mv Guerrero-Oviedo, María Camila
Moreno-Gomez , Freddy
author Guerrero-Oviedo, María Camila
author_facet Guerrero-Oviedo, María Camila
Moreno-Gomez , Freddy
author_role author
author2 Moreno-Gomez , Freddy
author2_role author
dc.subject.es-ES.fl_str_mv Dermatomiositis
Polimiositis
Terapéutica
Acciones farmacológicas
Miositis
topic Dermatomiositis
Polimiositis
Terapéutica
Acciones farmacológicas
Miositis
Polymyositis
Dermatomyositis
Treatment
Pharmacotherapy
Myositis
dc.subject.en-US.fl_str_mv Polymyositis
Dermatomyositis
Treatment
Pharmacotherapy
Myositis
description Dermatomyositis and polymyositis are rare autoimmune diseases, classified as inflammatory myopathies, clinically characterized by muscle weakness, frequently accompanied by extramuscular manifestations. Patients usually achieve remission or low levels of disease activity with initial treatment with glucocorticoids (may or may not be combined with immunomodulators), when this fails, it is considered refractory dermatomyositis and polymyositis (a new muscle biopsy must first be performed to rule out alternative diagnoses), thus additional treatments will be required for its management. The treatment of refractory dermatomyositis and polymyositis continues to be a challenge due to the lack of scientific evidence to validate the effectiveness of alternative drugs. This review presents some of the therapeutic alternatives. Biological therapies, especially rituximab and abatacept, were found in the literature as promising to reduce morbidity and mortality in both pathologies.
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2023-10-11T04:35:20Z
dc.date.available.none.fl_str_mv 2023-10-11T04:35:20Z
dc.date.none.fl_str_mv 2023-03-30
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
dc.type.es-ES.fl_str_mv Revisión de la literatura
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308
dc.identifier.uri.none.fl_str_mv https://vitela.javerianacali.edu.co/handle/11522/524
url https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308
https://vitela.javerianacali.edu.co/handle/11522/524
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308/1146
dc.rights.es-ES.fl_str_mv Derechos de autor 2023 Salutem Scientia Spiritus
https://creativecommons.org/licenses/by-nc-nd/4.0
rights_invalid_str_mv Derechos de autor 2023 Salutem Scientia Spiritus
https://creativecommons.org/licenses/by-nc-nd/4.0
dc.format.none.fl_str_mv application/pdf
dc.publisher.es-ES.fl_str_mv Pontificia Universidad Javeriana Cali
dc.source.en-US.fl_str_mv Salutem Scientia Spiritus; Vol. 9 No. 1 (2023): Revista Salutem Scientia Spiritus; 59-65
dc.source.es-ES.fl_str_mv Salutem Scientia Spiritus; Vol. 9 Núm. 1 (2023): Revista Salutem Scientia Spiritus; 59-65
dc.source.none.fl_str_mv 2463-1426
institution Pontificia Universidad Javeriana Cali
repository.name.fl_str_mv Repositorio Vitela
repository.mail.fl_str_mv vitela.mail@javerianacali.edu.co
_version_ 1812095056443604992

Publicaciones similares